Get the Stockscreener App
78.82
3.31%
-2.70
Pre-market:
78.82
Lemaitre Vascular Inc stock is traded at $78.82, with a volume of 219.88K.
It is down -3.31% in the last 24 hours and down -18.73% over the past month.
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
See More
Previous Close:
$81.52
Open:
$81.15
24h Volume:
219.88K
Relative Volume:
1.12
Market Cap:
$1.77B
Revenue:
$213.03M
Net Income/Loss:
$41.32M
P/E Ratio:
43.07
EPS:
1.83
Net Cash Flow:
$33.49M
1W Performance:
-4.45%
1M Performance:
-18.73%
6M Performance:
-12.12%
1Y Performance:
+18.33%
1-Day Range:
$78.79
$82.42
1-Week Range:
$78.79
$84.46
52-Week Range:
$62.39
$109.58
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LMAT
Lemaitre Vascular Inc
|
78.82 | 1.77B | 213.03M | 41.32M | 33.49M | 1.83 |
|
ISRG
Intuitive Surgical Inc
|
476.78 | 170.05B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.79 | 63.97B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
86.81 | 42.94B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.72 | 32.28B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.55 | 17.64B | 17.28B | 108.00M | 391.00M | 0.20 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
Down -15.37% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround - Nasdaq
Smartleaf Asset Management LLC Buys 293 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) - Defense World
Bank of New York Mellon Corp Lowers Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) - Defense World
Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) PT at $95.25 - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Will Pay A Larger Dividend Than Last Year At $0.20 - Yahoo Finance
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year - Simply Wall St
Ex-Dividend Reminder: LeMaitre Vascular, Mercury General and CBL & Associates Properties - Nasdaq
(LMAT) Investment Analysis - Stock Traders Daily
Geneva Capital Management LLC Has $79.76 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) - MarketBeat
Bahl & Gaynor Inc. Has $11.26 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) - MarketBeat
Independent Director Lawrence Jasinski Sold A Bunch Of Shares In LeMaitre Vascular - Simply Wall St
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Looks Like A Good Stock, And It's Going Ex-Dividend Soon - Yahoo Finance UK
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
LeMaitre Vascular, Inc. to Host Earnings Call - ACCESS Newswire
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces Dividend Increase$0.20 Per Share - MarketBeat
Q3 Earnings Estimate for LMAT Issued By Barrington Research - MarketBeat
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know - MSN
Insider Sell: Lawrence Jasinski Sells Shares of LeMaitre Vascula - GuruFocus.com
LeMaitre Vascular director sells $289,064 in stock - Investing.com
LeMaitre Vascular director sells $289,064 in stock By Investing.com - Investing.com UK
3 Best Earnings Growth Stocks to Buy in March: CAKE, LMAT, HURN - Yahoo Finance
Sanctuary Advisors LLC Has $207,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) - Defense World
13,432 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Acquired by Illumine Investment Management LLC - MarketBeat
Principal Financial Group Inc. Boosts Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Shares Gap DownHere's What Happened - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Stock Price Expected to Rise, Lake Street Capital Analyst Says - MarketBeat
Best Momentum Stocks to Buy for March 4th - Nasdaq
Stentless Bioprostheses Market Is Booming Worldwide 2025-2032 - openPR
LeMaitre Vascular (NASDAQ:LMAT) Downgraded to "Market Perform" Rating by Oppenheimer - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Updates Q1 2025 Earnings Guidance - MarketBeat
LeMaitre to Participate at Upcoming Investor Conferences in March - GlobeNewswire
LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2025 Earnings Guidance - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Cut to Market Perform at Barrington Research - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Cut to “Market Perform” at Barrington Research - Defense World
LeMaitre Vascular (NASDAQ:LMAT) Cut to “Market Perform” at Oppenheimer - Defense World
LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $110.00 - Defense World
Truist Financial Corp Has $822,000 Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) - Defense World
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105 - Simply Wall St
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):